CN113495148A

CN113495148A - Application of urine hemagglutinin protein and polypeptide fragment thereof in gestational diabetes

Info

Publication number: CN113495148A
Application number: CN202010194291.8A
Authority: CN
Inventors: 张曼; 胡智颖
Original assignee: Beijing Shijitan Hospital
Current assignee: Beijing Shijitan Hospital
Priority date: 2020-03-19
Filing date: 2020-03-19
Publication date: 2021-10-12

Abstract

The invention provides application of urine Hemagglutinin (HPX) protein and polypeptide fragments thereof, in particular to application of the urine hemagglutinin protein and the polypeptide fragments thereof in preparing preparations for detecting gestational diabetes related diseases. The research proves that compared with the normal gestational group, the expression of the hemagglutinin protein and the polypeptide fragment thereof in the gestational diabetes group is reduced, and the hemagglutinin protein and the polypeptide fragment thereof can be used for detecting, monitoring and auxiliary diagnosis related to the gestational diabetes. The invention exerts the advantages of noninvasive acquisition, large-scale repeated sampling and convenient preservation of the urine specimen, and utilizes the urine specimen to detect the urine hemagglutinin protein and the polypeptide fragment thereof.

Description

Application of urine hemagglutinin protein and polypeptide fragment thereof in gestational diabetes

Technical Field

The invention relates to new application of urine hemagglutinin protein and polypeptide fragments thereof, in particular to application of urine hemagglutinin protein and polypeptide fragments thereof in preparing preparations for detecting correlation of gestational diabetes.

Background

In the process of pregnancy, in order to meet the requirements of fetal growth and development, a series of changes occur in the reproductive, blood circulation, urinary, respiratory, digestive and endocrine systems of pregnant women, especially in the endocrine system, the secretion of gonadotropin is reduced, and the secretion of prolactin, thyroid stimulating hormone, adrenocorticotropic hormone, glucocorticoid, aldosterone, thyroid hormone and the like is increased. In the middle and late gestation period, part of pregnant women have reduced insulin sensitivity, and have decomposition and antagonism on insulin, so that insulin activity is reduced, and the pregnant women can not normally compensate the physiological change to cause Gestational Diabetes (GDM). If the blood sugar level is not well controlled, the incidence rate of adverse pregnancy fatalities of gestational diabetes women in gestational period hypertension diseases, abortion, cesarean section, premature delivery, neonatal hypoglycemia, neonatal hyperbilirubinemia and the like is obviously higher than that of normal pregnant and lying-in women. For the patients with gestational diabetes who are diagnosed, the later blood sugar control standard and control requirement are stricter, and the monitoring is more frequent. The method aims to improve the life quality and medical compliance of the gestational diabetes patients, relieve the pain of blood sampling for multiple times of gestational blood sugar detection, and formulate more refined and personalized monitoring indexes aiming at different gestational periods, and hope to realize painless, convenient, rapid and easily repeated urine detection or monitoring of the in vivo sugar level and sugar metabolism condition through the research of urine protein or polypeptide, and also lay a foundation for the further research of the urine polypeptide detection kit.

Human hemagglutinin is a plasma beta-glycoprotein that specifically binds a heme, has high affinity, and transports it to hepatocytes to rescue iron. Hemagglutinin also has significant anti-apoptosis, anti-oxidant and immunoregulatory effects, participates in the cell differentiation process, and is involved in extracellular matrix reconstruction. The reduction of the serum content is commonly seen in severe hemolytic anemia, severe malignant malnutrition, liver benign and malignant diseases and the like. In the study of related diseases of pregnancy, the serum human hemagglutinin level of a patient with preeclampsia is found to be obviously reduced. The absence of the hemoglobin/hemagglutinin clearance mechanism is associated with the onset of preeclampsia.

Compared with the common clinical blood sample, the urine can be collected in a non-invasive, continuous and large amount; without homeostatic regulation, more various and larger changes can be accumulated, and many pathophysiological changes of the body can be reflected in urine. Some protein polypeptides with relatively small molecular weight, such as hormones and cytokines, are excreted into urine quickly after entering blood, and the probability that the proteins and polypeptides are detected in urine is much higher than that in blood; before urine is collected, a possible protein degradation process in urine is completed, so that urine protein can be kept stable for a longer time. In order to relieve the pain of blood glucose detection of GDM patients in blood sampling for multiple times, the experiment hopes to realize monitoring and understanding of the glucose level and the glucose metabolism level in GDM patients through detection of urine protein or polypeptide on the basis of the previous methodology exploration.

Disclosure of Invention

The invention aims to provide application of urine hemagglutinin protein and polypeptide fragments thereof in preparing preparations for detecting correlation of gestational diabetes.

Preferably, the amino acid sequence of the urine hemagglutinin protein is shown as SEQ ID NO.1 (MARVLGAPVA LGLWSLCWSL AIATPLPPTS AHGNVAEGET KPDPDVTERC SDGWSFDATT LDDNGTMLFF KGEFVWKSHK WDRELISERW KNFPSPVDAA FRQGHNSVFL IKGDKVWVYP PEKKEKGYPK LLQDEFPGIP SPLDAAVECH RGECQAEGVL FFQGDREWFW DLATGTMKER SWPAVGNCSS ALRWLGRYYC FQGNQFLRFD PVRGEVPPRY PRDVRDYFMP CPGRGHGHRN GTGHGNSTHH GPEYMRCSPH LVLSALTSDN HGATYAFSGT HYWRLDTSRD GWHSWPIAHQ WPQGPSAVDA AFSWEEKLYL VQGTQVYVFL TKGGYTLVSG YPKRLEKEVG TPHGIILDSV DAAFICPGSS RLHIMAGRRL WWLDLKSGAQ ATWTELPWPH EKVDGALCME KSLGPNSCSA NGPGLYLIHG PNLYCYSDVE KLNAAKALPQ PQNVTSLLGC TH); or an amino acid sequence derived from the amino acid sequence shown in SEQ ID NO.1 and having the same function as the amino acid sequence shown in SEQ ID NO.1, y and a nucleic acid sequence encoding the amino acid sequence.

Preferably, the urine hemagglutinin protein and the polypeptide fragment thereof are low expressed in gestational diabetes patients.

Preferably, the preparation is a urine hemagglutinin protein of a gestational diabetes patient and a polypeptide fragment detection kit thereof.

Preferably, the kit comprises one or more of an aptamer antibody or antibody fragment capable of specifically binding to human hemagglutinin protein and polypeptide fragments thereof.

Preferably, the kit further comprises a component selected from the group consisting of: carrier, diluent, reference substance, standard substance, quality control substance, detection antibody, second antibody diluent, luminescent reagent, washing solution, developing solution and stop solution.

Preferably, the standard comprises a human hemagglutinin protein standard, a humanized tag antibody standard; preferably, the quality control product comprises: human hemagglutinin protein quality control product, humanized label antibody quality control product; preferably, the carrier comprises: microparticles, microspheres, slides, test strips, plastic beads, liquid phase chips, microwell plates, or affinity membranes.

Preferably, the solid phase carrier is made of any one of polyvinyl chloride, polystyrene, polyacrylamide and cellulose.

The inventor firstly collects urine samples of normal pregnant women and pregnant diabetics, takes supernate after centrifugation, and utilizes weak cation exchange magnetic beads to purify and separate the urine samples. Uniformly mixing 1 mu l of sample and 10 mu l of matrix, taking 1 mu l of point on an Anchorchip target plate, ionizing the sample, carrying out mass spectrometry, and collecting data within the range of 1000-10000Da to obtain a mass spectrometry polypeptide diagram consisting of protein peaks with different mass-to-charge ratios. All mass spectrograms of normal pregnant women and the pregnant diabetes group were analyzed using the BioExplorer analysis software to screen for differential polypeptides. Then, the inventor carries out matrix-assisted laser desorption ionization time-of-flight mass spectrometry identification on the differential polypeptide with statistical significance, and searches a database to obtain the hemagglutinin protein with differential expression, wherein the hemagglutinin protein is low in the urine of the gestational diabetes group compared with the normal pregnancy group.

The research proves that compared with the normal pregnancy group, the hemagglutinin protein and the polypeptide fragment thereof have low expression in urine of patients with gestational diabetes. Therefore, the detection of the urine hemagglutinin protein and the polypeptide fragment thereof can be used for detecting, monitoring or auxiliary diagnosis of the gestational diabetes.

The invention exerts the advantages of noninvasive acquisition, large-scale repeated sampling and convenient preservation of the urine specimen, and utilizes the urine specimen to detect the hemagglutinin protein and the polypeptide fragment thereof.

In order to make the aforementioned and other objects, features and advantages of the present invention comprehensible, preferred embodiments accompanied with figures are described in detail below.

Drawings

FIG. 1 is a graph showing peak area distribution of urine hemagglutinin protein in normal pregnant women and patients with gestational diabetes.

FIG. 2 is a scatter plot of urine hemagglutinin protein expression for normal pregnant women and patients with gestational diabetes.

FIG. 3 is a ROC curve of hemagglutinin protein expression in urine of gestational diabetes patients.

Detailed Description

Example 1Collection and processing of urine specimens

Collecting 78 clean mid-section urine specimens of normal pregnant women (N) and clinical diagnosis gestational diabetes patients (GDM) with the ages of 15-49 years for 30 routine obstetrical examinations in obstetrical department outpatients of Beijing century altar Hospital affiliated to capital medical university. The gestational diabetes patients (GDM group) meet the diagnosis and treatment standard of diabetes of American Diabetes Association (ADA) of 2011, and do not combine acute and chronic infection, tumor, cardiovascular diseases and serious liver and kidney dysfunction. 78 gestational diabetes patients were divided into GM1 (FPG. ltoreq.4.50 mmol/L) and GM2 (FPG. gtoreq.4.50 mmol/L) groups according to OGTT test (Oral Glucose clinical, OGTT) Fasting blood Glucose (FPG) level. After urine collection, 400 Xg centrifugation for 5min, supernatant was collected and split charged and frozen at-80 ℃. Clinical characteristics of the subjects are shown in Table 1-1.

Example 2Magnetic bead purification and urine polypeptide screening

And (3) enriching the polypeptide in the urine by using weak cation exchange magnetic beads, and analyzing the polypeptide spectrum in the urine by using a matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS). After calibration of the instrument with standards, 1. mu.l of the eluate was mixed with 10. mu.l of matrix (0.3% of. alpha. -cyano-4-hydroxycinnamic acid, HCCA) and 1. mu.l of the spot was applied to an Anchorchip (Autoflex MALDI TOF, Bruker-Dalton) target plate and dried at room temperature. And ionizing the sample by irradiating the nitrogen laser, and then carrying out mass spectrometry, and acquiring data in the range of 1000-10000Da to obtain a mass spectrogram consisting of protein peaks with different mass-to-charge ratios. For each MALDI crystallisation spot, a total of 400 laser shots (50 shots at each of the 8 different positions of each crystallisation spot) were made, and the average represented a sample, thereby obtaining a polypeptide profile for all samples. Three biological replicates were performed per sample. The mass spectrograms of normal pregnant women (N) and Gestational Diabetes Mellitus (GDM) groups were analyzed using BioExplorer analysis software to screen differential polypeptides. The polypeptide peak of mass to charge ratio (m/z) 1142.9 had statistical differences between the 2 groups (P < 0.05), with the distribution of the mean peak areas as shown in figure 1.

Example 3Identification and analysis of differential Polypeptides

From the sample tube, 20ul was taken for LC-MS/MS analysis. An EASY-nLC1000 HPLC system was used for the separation. Liquid phase a was 0.1% formic acid in acetonitrile (2% acetonitrile) and liquid phase B was 0.1% formic acid in acetonitrile (98% acetonitrile). The 100% A solution was equilibrated on a 100X 100mm BEHnanoACquisity column at a flow rate of 400 nl/min. The chromatographic spray needle is PN: FS 360-20-10-N-20-C12. Samples were separated by capillary HPLC and analyzed by Q-exact mass spectrometer (Thermo). The ion source voltage is 3.5kv, the analysis time is 120min, and the scanning range of the parent ion is 300-2000 m/z. The mass-to-charge ratios of the polypeptides and polypeptide fragments were collected by collecting 20 fragments (MS 2scan, HCD) after each complete scan. At M/Z200, the MS1 resolution was 70,000, and the MS2 resolution was 17,500. Data analysis software PD (Proteome scanner 1.4, thermo) was used for the search. The search database is Mascot. The parent ion error was set to 20ppm, the fragment ion error was set to 1Da, the digestion mode was non-digestion, and the modification was oxidation (M) of methionine. Data card value, Percolator algorithm, FDR < 1%. The differentially expressed polypeptide peak of mass to charge (m/z) 1142.9 was retrieved from the database and identified as hemagglutinin protein.

The expression of hemagglutinin protein was low in urine of patients with Gestational Diabetes Mellitus (GDM) compared to that of the normal pregnancy group, and as shown in fig. 2, there was a significant difference in the expression of hemagglutinin protein in urine of both normal pregnant women and patients with gestational diabetes mellitus.

Further, the inventor detects 1142.9 polypeptide peak values in the urine of 78 gestational diabetes patients and 30 normal pregnant women, establishes an ROC curve, the area under the curve is 0.690, and as shown in figure 3, the sensitivity and specificity of the reactive hemagglutinin are good.

Although the present invention has been described with respect to the preferred embodiments, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.

Sequence listing

<110> Beijing century bed Hospital affiliated to capital medical university

<120> application of urine hemagglutinin protein and polypeptide fragment thereof in gestational diabetes

<130> 20PHPX-CN

<160> 1

<170> SIPOSequenceListing 1.0

<210> 1

<211> 462

<212> PRT

<213> urinary hemopexin protein

<400> 1

Met Ala Arg Val Leu Gly Ala Pro Val Ala Leu Gly Leu Trp Ser Leu

1 5 10 15

Cys Trp Ser Leu Ala Ile Ala Thr Pro Leu Pro Pro Thr Ser Ala His

20 25 30

Gly Asn Val Ala Glu Gly Glu Thr Lys Pro Asp Pro Asp Val Thr Glu

35 40 45

Arg Cys Ser Asp Gly Trp Ser Phe Asp Ala Thr Thr Leu Asp Asp Asn

50 55 60

Gly Thr Met Leu Phe Phe Lys Gly Glu Phe Val Trp Lys Ser His Lys

65 70 75 80

Trp Asp Arg Glu Leu Ile Ser Glu Arg Trp Lys Asn Phe Pro Ser Pro

85 90 95

Val Asp Ala Ala Phe Arg Gln Gly His Asn Ser Val Phe Leu Ile Lys

100 105 110

Gly Asp Lys Val Trp Val Tyr Pro Pro Glu Lys Lys Glu Lys Gly Tyr

115 120 125

Pro Lys Leu Leu Gln Asp Glu Phe Pro Gly Ile Pro Ser Pro Leu Asp

130 135 140

Ala Ala Val Glu Cys His Arg Gly Glu Cys Gln Ala Glu Gly Val Leu

145 150 155 160

Phe Phe Gln Gly Asp Arg Glu Trp Phe Trp Asp Leu Ala Thr Gly Thr

165 170 175

Met Lys Glu Arg Ser Trp Pro Ala Val Gly Asn Cys Ser Ser Ala Leu

180 185 190

Arg Trp Leu Gly Arg Tyr Tyr Cys Phe Gln Gly Asn Gln Phe Leu Arg

195 200 205

Phe Asp Pro Val Arg Gly Glu Val Pro Pro Arg Tyr Pro Arg Asp Val

210 215 220

Arg Asp Tyr Phe Met Pro Cys Pro Gly Arg Gly His Gly His Arg Asn

225 230 235 240

Gly Thr Gly His Gly Asn Ser Thr His His Gly Pro Glu Tyr Met Arg

245 250 255

Cys Ser Pro His Leu Val Leu Ser Ala Leu Thr Ser Asp Asn His Gly

260 265 270

Ala Thr Tyr Ala Phe Ser Gly Thr His Tyr Trp Arg Leu Asp Thr Ser

275 280 285

Arg Asp Gly Trp His Ser Trp Pro Ile Ala His Gln Trp Pro Gln Gly

290 295 300

Pro Ser Ala Val Asp Ala Ala Phe Ser Trp Glu Glu Lys Leu Tyr Leu

305 310 315 320

Val Gln Gly Thr Gln Val Tyr Val Phe Leu Thr Lys Gly Gly Tyr Thr

325 330 335

Leu Val Ser Gly Tyr Pro Lys Arg Leu Glu Lys Glu Val Gly Thr Pro

340 345 350

His Gly Ile Ile Leu Asp Ser Val Asp Ala Ala Phe Ile Cys Pro Gly

355 360 365

Ser Ser Arg Leu His Ile Met Ala Gly Arg Arg Leu Trp Trp Leu Asp

370 375 380

Leu Lys Ser Gly Ala Gln Ala Thr Trp Thr Glu Leu Pro Trp Pro His

385 390 395 400

Glu Lys Val Asp Gly Ala Leu Cys Met Glu Lys Ser Leu Gly Pro Asn

405 410 415

Ser Cys Ser Ala Asn Gly Pro Gly Leu Tyr Leu Ile His Gly Pro Asn

420 425 430

Leu Tyr Cys Tyr Ser Asp Val Glu Lys Leu Asn Ala Ala Lys Ala Leu

435 440 445

Pro Gln Pro Gln Asn Val Thr Ser Leu Leu Gly Cys Thr His

450 455 460

Claims

1. Application of urine Hemagglutinin (HPX) and its polypeptide fragment in preparing preparation for detecting gestational diabetes is provided.

2. The use of claim 1, wherein the amino acid sequence of the urinary hemagglutinin protein is shown in SEQ ID No. 1; or an amino acid sequence which is derived from the amino acid sequence shown in SEQ ID NO.1 and has the same function with the amino acid sequence shown in SEQ ID NO.1, and a nucleic acid sequence for coding the amino acid sequence.

3. The use of claim 1, wherein the urinary hemagglutinin protein and the polypeptide fragments thereof are low expressed in gestational diabetes patients.

4. The use of claim 1, wherein the preparation is a kit for detecting the hemagglutination protein and polypeptide fragments thereof from urine of patients with gestational diabetes.

5. The use of claim 4, wherein the kit comprises one or more of an aptamer antibody or antibody fragment that specifically binds to human hemagglutinin protein and polypeptide fragments thereof.

6. The use according to claim 4, wherein the kit further comprises a component selected from the group consisting of: carrier, diluent, reference substance, standard substance, quality control substance, detection antibody, second antibody diluent, luminescent reagent, washing solution, developing solution and stop solution.

7. The use of claim 6, wherein the standard comprises a human hemagglutinin protein standard, a humanized tag antibody standard; preferably, the quality control product comprises: human hemagglutinin protein quality control product, humanized label antibody quality control product; preferably, the carrier comprises: liquid phase or solid phase carriers such as particles, microspheres, glass slides, test strips, plastic beads, liquid phase chips, micro-porous plates or affinity membranes.

8. The use of claim 7, wherein the solid phase carrier is made of any one of polyvinyl chloride, polystyrene, polyacrylamide and cellulose.